glp 1 for mental health Transformation 2.0: The GLP-1 RAs as Psychiatric Medications? GLP-1 Receptor Agonists in Mood

This 72-week study compared the efficacy and safety of subcutaneous semaglutide 7.2 mg against semaglutide 2.4 mg and a placebo, all administered weekly, in 1,407 adults with obesity who also participated in lifestyle interventions

These effects can be managed through dietary modifications but may affect treatment adherence

In contrast, patients treated with Ozempic often experience more substantial weight loss, averaging approximately 1015% or more of their initial body weight over the same time frame, especially at higher dosages

Delayed absorption, amplified side effects, and hypoglycemia risk for some patients make moderation essential